Original Contributions |
From the University of Pittsburgh, Pa (L.K.); the Cardiovascular Health Study Coordinating Center, Seattle, Wash (L. Fisher, R.M.); Johns Hopkins University, Baltimore, Md (L. Fried); the University of Vermont, Burlington (M.C.); Bowman Gray School of Medicine, Winston-Salem, NC (S.J.); and the National Heart, Lung, and Blood Institute, Bethesda, Md (T.M.).
Correspondence to Lewis H. Kuller, MD, DrPH, University of Pittsburgh, Department of Epidemiology, GSPH, 130 DeSoto St, Pittsburgh, PA 15261. E-mail kuller+{at}pitt.edu
| Abstract |
|---|
|
|
|---|
65
years) was 41.3% for white women, 39.7% for black women, 41.9% for
white men, and 43.7% for black men. The prevalence increased with age.
The risk factor associations for subclinical disease were similar among
blacks and whites. In multivariate analysis,
age, systolic blood pressure, LDL cholesterol,
smoking, and family history of myocardial infarction were independently
associated with subclinical disease among both black and white women,
while for white men, systolic blood pressure, use of
antihypertensive medication, smoking, body mass index, and
diastolic blood pressure (inverse) were related to
subclinical disease. In black men, blood triglyceride
level, use of antihypertensive medications, and family history of
myocardial infarction (inverse) were associated with subclinical
disease.
Key Words: cardiovascular disease race risk factors subclinical disease
| Introduction |
|---|
|
|
|---|
There were 153 black women (5.2%) and 91 black men (4.1%) aged
65
years among the original 5201 CHS participants recruited in 1989 to
1990 (year 1 of the CHS). In 1992 to 1993 (year 4 of the study), a
larger cohort, consisting of 424 black women and 248 black men, was
added to the CHS. The recruitment methods, using the Medicare
participant files as a sampling frame, were the same as those for the
baseline population in 1989 to 1990.3 This study
includes the total sample of blacks from both the baseline recruitment
and the sample added with their baseline examination in year 4 of their
examinations. The black participants are compared with the entire
sample of white participants who had their baseline examination in 1989
to 1990.3
In the initial report of black/white comparisons in the
CHS,3 black men and women had greater common
carotid artery wall thickness than whites but lesser internal carotid
artery wall thickness. Whites had a higher prevalence of carotid artery
stenosis
50%. Blacks had a much higher prevalence of
decreased ankle/brachial blood pressure
0.9 than whites, especially
among black men, and greater echocardiographic and
electrocardiographic evidence of increased left ventricular
mass. Isolated ST-T segment abnormality and conduction defects on ECG
were similar between blacks and whites. Atrial fibrillation prevalence
was slightly higher in whites than blacks.3
A composite subclinical cardiovascular disease measure
was developed in the CHS based on the extent of intimal-medial
thickness of the carotid artery
80th percentile and ankle/brachial
blood pressure
0.9, major electrocardiographic abnormalities
according to the Minnesota code, echocardiographic
abnormalities of wall motion and ejection fraction, and positive
response on the Rose questionnaire for either claudication or possible
angina pectoris.1 The prevalence of subclinical
disease by this definition was very high at the baseline examination;
39.0% of all men and 35.9% of women age
65 years had evidence of
subclinical but no evidence of clinical cardiovascular
disease at baseline examinations in 1989 to 1990. The prevalence of
subclinical cardiovascular disease increased with age
in both men and women. Independent risk factors for subclinical disease
included age, higher systolic blood pressure and LDL-C, lower
HDL-C, higher fasting glucose, current smoking, and an elevated white
blood cell count for women and age, systolic blood pressure,
glucose, current smoking, and a history of high blood pressure in men,
based on logistic regression analysis.1
There were not enough black participants in the original baseline
sample in 1989 to 1990 for a comparison of risk factors for this
composite index of subclinical disease between blacks and whites.
In this study we have determined (1) the prevalence of clinical, subclinical, and no disease among men and women, both black and white, in the Cardiovascular Health Study and (2) the association for both blacks and whites between clinical, subclinical, and no disease and cardiovascular risk factors.
| Methods |
|---|
|
|
|---|
65 years. There were 5201 participants in
the original sample, including 2955 women and 2246 men. Only 153 black
women and 91 black men in the original sample were recruited in 1989 to
1990, the baseline year of the CHS. In 1993 to 1994, year 4 of the study, a new cohort of 248 black men and 424 women was added to the study. The recruitment of the new black participants was similar to that for the original cohort of white and black participants. They were recruited from lists of Medicare beneficiaries in three of the four CHS communities: Pittsburgh, Pa, Winston-Salem, NC, and Sacramento, Calif. Eligible participants were ambulatory, expected to reside in the area for the next 3 years, able to give informed consent, and did not require a proxy response at baseline. Clinical cardiovascular disease at baseline was not an exclusion criterion.6
The baseline evaluation included a home interview and physical
examination in the clinic. The components of these evaluations have
been published.4 Prevalent
cardiovascular disease was determined at baseline in
year 1 for the original cohort and in year 4 for the new cohort, by
self-report. Clinical cardiovascular disease was
defined as a confirmed history of heart disease, including MI, angina
pectoris, or use of nitroglycerine; congestive heart
failure; coronary bypass surgery; atrial fibrillation, as
detected by ECG (or use of a cardiac pacemaker); history of stroke,
transient ischemic attack, or carotid artery
surgery1 ; or history of intermittent claudication
or peripheral vascular surgery (Table 1
).1
|
Subclinical cardiovascular disease was defined as in
the previous study1 2 and in the introduction to
this study (ankle/arm index
0.9, internal carotid wall thickness
>80th percentile, common carotid wall thickness >80th percentile,
carotid stenosis >25%, major electrocardiographic
abnormalities, Rose questionnaire claudication positive, or Rose
questionnaire angina positive).
The echocardiogram was not done in year 4, ie, baseline for the new black cohort, but was done later, in year 6. Echocardiographic abnormalities as a measure of subclinical disease have therefore been excluded from this study for both blacks and whites. At the baseline evaluation there were only 45 women (4.2%) and 66 men (7.6%) that had either an abnormal ejection fraction or wall motion abnormalities on the echocardiogram that were considered a measure of subclinical disease, excluding participants with clinical disease.1 In the original classification, only 11 participants with subclinical disease had wall motion or ejection fraction abnormalities as their only criterion for classification of subclinical disease.
The differences in the time of the baseline examination between the "new" black cohort recruited in 1992 to 1993 and the original predominantly white cohort recruited in 1989 to 1990 could present a potential bias if methods of data collection changed during the 3 years between examinations. To reduce this potential bias, the measurements of carotid duplex scanning at year 1 were reread, using the same readers who had read the year 4 carotid studies. The ECGs were read in the same laboratory using similar criteria. The ankle/brachial blood pressure was measured in the same way at years 1 and 4, and quality control methods were monitored in the study to assure consistency over time in laboratory methods. We compared the risk factor levels for blacks in the 1989 to 1990 with the 1992 to 1993 cohort. There were no consistent differences in the risk factors.
There were 244 blacks in the original cohort (91 men and 153 women) and
672 in the new cohort (248 men and 424 women) in year 4. The mean
values of risk factors in the original black cohort and the new black
cohort were, respectively, age 72.6 and 73.1 years,
diastolic blood pressure 75 and 75 mm HG (NS),
systolic blood pressure 141 and 142 mm Hg (NS), BMI 28
and 29 kg/(m)2 (NS), cholesterol 207
and 210 mg/dL (NS), and fasting glucose 120 and 119 mg/dL (NS). A
history of current cigarette smoking and alcohol use was also similar
between the original and new cohorts. A history of MI was reported by
19% of the original and 15% of the new cohort (NS), stroke 7.4% and
9.8%, diabetes 22% and 21% (NS), and history of hypertension 63%
and 68% (NS). The only significant difference between the two cohorts
was use of antihypertensive therapy, at 55% in the original and 63%
in the new cohort, which could be a time-dependent change in the
community. If the prevalence of antihypertensive drug use had been 63%
at both time periods, the number of blacks on drug therapy would have
been 578 rather than 559 of 971 participants (Table 2
).
|
Statistical Methods
All analyses excluded those individuals not classified
as either white or black. Potential categorical risk factors for
subclinical disease that were examined included history of
hypertension, history of diabetes, familial history of MI in a
first-degree relative aged <65 years, current smoking, use of
antihypertensive medications, and use of lipid-lowering medications.
Continuous risk factors considered included age, systolic blood
pressure, diastolic blood pressure, BMI, WHR, total
cholesterol, LDL-C, HDL-C, triglycerides,
fasting glucose, serum insulin, and white blood cell count.
All risk factors of interest were compared across races stratified by sex and disease status (where disease status is either clinical, subclinical, or no disease). For the categorical risk factors, age-adjusted percentages were calculated by using a logistic regression model with the risk factor as the dependent variable and age as the explanatory variable. A separate model was fit for each disease/sex/race combination, and these models were then used to predict the proportion of participants with the risk factor of interest within each stratum, adjusted for age. The age-adjusted significance levels were based on an age-adjusted logistic regression model for the risk factor of interest. For continuous risk factors, age-adjusted means were calculated for each disease/sex/race stratum. These means were recalculated, excluding those participants using antihypertensive medication. The significance levels were based on an analysis of variance model for the risk factor of interest, adjusted for age.
Logistic regression was used to model the risk of subclinical disease, excluding those individuals with clinical disease. The analysis was stratified by sex and race. Within each sex/race stratum, variables were entered into the model using a forward stepwise selection procedure beginning with all of the risk factors listed above. For comparison between races, an expanded model was fit using a common set of explanatory variables across races within a sex (the union of the variables selected in the forward stepwise procedures).
Logistic regression was used to obtain a model for each outcome, with age as the explanatory variable. A separate model was fit for each disease/sex/race combination, and this model was used to predict the percentages (evaluated at the mean age for the white population in the original cohort). The significance levels are based on the Wald statistic in a logistic regression. For any effect, the probability value is adjusted for age, as well as any other effects of the same or lower order. For example, the two-way interactions are adjusted for age, all main effects, and all other two-way interactions. Note that different models were used to arrive at the predicted values versus the probability values.
All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS for Windows), release 6.1. (Probability values are shown in the tables).
| Results |
|---|
|
|
|---|
80 years.
Prevalence of Subclinical and Clinical Disease
The prevalence of clinical cardiovascular disease
was 26.2% among white women, 35.4% among black women, 37.2% among
white men, and 37.3% among black men (Tables 1
and 3
). There was a higher prevalence of
stroke, MI, angina pectoris, and congestive heart failure in black
women than in white women (Table 1
). There was a higher prevalence of
stroke and a lower prevalence of bypass surgery and/or angioplasty in
black men than in white men. It is important to note that any
participant could have more than one clinical disease or procedure
(Table 1
).
|
The prevalence of subclinical disease at baseline among all CHS
participants (Table 3
) was similar in black and white men and women.
The prevalence was higher in men than women. Blacks had significantly
lower ankle/brachial blood pressure, greater common carotid artery wall
thickness
80th percentile, and higher prevalence of major
electrocardiographic abnormalities, while whites had a much higher
prevalence of carotid artery stenosis (Table 4
). The prevalence of subclinical and
clinical disease increased with age in all four race/sex groups (Figs 1
and 2
).
|
|
|
Risk Factors and Subclinical and Clinical Disease, Discrete
Variables
The distribution of discrete and continuous risk factors in Tables 5
and 6
are
shown by clinical, subclinical, and no-disease categories and by
comparison by sex and race and possible interaction terms.
|
|
The distribution of categorical diseases, diabetes, and hypertension was as expected. The prevalence was highest in participants with clinical disease, next highest with subclinical disease, and lowest for those with no disease for all four race and sex groups. The prevalence of hypertension was higher in blacks than whites. Even in older individuals (except for black men), a history of MI in a first-degree relative <65 years of age was more prevalent in those with clinical disease (and next for subclinical disease) than in those with neither subclinical nor clinical disease.
The use of antihypertensive medications was lowest in participants with
no disease and highest in those with clinical disease. The use of
antihypertensive medication was higher among blacks than whites,
especially for black women. The use of lipid-lowering drugs was much
less than of antihypertensive drug therapy (Table 5
) and was higher for
clinical disease and subclinical disease than for those with no
disease.
A history of current cigarette smoking provided a somewhat different pattern, in that the highest prevalence was found among individuals with subclinical disease and next for clinical disease, with the lowest prevalence in those with no disease. The percent of current smoking was higher among blacks with subclinical disease and was about twice as high as for the no-disease group among blacks.
Continuous Variables
The association of continuous risk factors (Table 6
) with clinical
disease was also similar among the four race and sex groups and was
also consistent with risk factors for clinical disease among
younger individuals. The levels of systolic blood pressure,
LDL-C, triglycerides, fasting glucose, and insulin were
higher for individuals with either subclinical or clinical disease than
for those with no disease. There was a weak, but overall significant,
association of BMI and WHR with subclinical and clinical disease
compared with no disease. White men and black women with subclinical
and clinical disease had higher BMIs than those with no subclinical
disease. Similarly, for WHR, the differences among the three categories
were relatively small.
HDL-C levels were, as expected, higher in women than in men and higher in blacks than in whites, lowest for individuals with clinical disease, and higher for individuals with no disease. Black women with no subclinical or clinical disease had HDL-C levels that were 19 mg/dL higher than levels in white men with clinical disease.
The diastolic blood pressure varied little among the three disease categories. In general, the levels were highest for participants with no subclinical or clinical disease and lower for those with clinical disease.
The white blood cell count, which may be a measure of inflammation related to atherosclerosis, was highest for individuals with clinical disease and lowest for those with neither subclinical nor clinical disease for all four race and sex groups. White blood cell counts were higher in whites than in blacks, consistent with previous studies.7
The high prevalence of antihypertensive drug use in this study and the
possible effects of antihypertensive drugs such as diuretics
and beta-blockers on other risk factors, especially blood pressure,
lipids, and glucose, could effect the associations noted in Tables 5
and 6
. The entire analysis of risk factors and disease was
repeated, excluding those who were on antihypertensive therapy. The
risk factor analysis for the relationships of subclinical,
clinical, and no subclinical or clinical disease was similar to that
for the entire sample, which included the participants on
antihypertensive therapy.
The next assessment was limited to participants with either subclinical
or no subclinical and clinical disease, using bivariate
analyses similar to those in Tables 5
and 6
. For white women,
significant differences were found for all of the risk factors listed
in Table 6
except BMI; for black women, systolic blood
pressure, WHR, LDL-C, and HDL-C; for white men, age, systolic
blood pressure, BMI, WHR, HDL-C, triglycerides, and fasting
glucose; and for black men, age only (data not shown);
P<.05 between subclinical and no subclinical disease. For
categorical variables similar to Table 5
, current cigarette smoking
was significantly greater among those with subclinical disease for all
four race and sex groups. A history of diabetes was more frequent among
subclinical disease for all groups except black men, and hypertension
history more frequent for all groups except black
women. Family history of coronary heart disease was more
frequent for white women with subclinical disease than for those with
no subclinical disease (not shown).
Regression Analysis
The results of forward stepwise logistic regression
analysis of the risk factors for the composite index of
subclinical disease, excluding those individuals with clinical disease,
are shown by race and sex in Table 7
.
|
Current smoking and indicators of elevated blood pressure (either
measured systolic blood pressure or history of hypertension)
were significantly related to subclinical disease in all four race and
sex groups in multivariate models (Table 7
). LDL-C and
fasting blood glucose (in whites) were significant independent
predictors of subclinical disease in women, but not in men. White blood
cell count and family history of MI were significant independent
predictors of subclinical disease in white women. BMI was significantly
different between subclinical and no subclinical disease for white men
only in both univariate and multivariate
models (Table 7
). Although WHR was a significant independent predictor
in bivariate analyses, the addition of blood pressure measures,
LDL-C, and BMI to the multivariate model reduced WHR as
a significant variable for white women, black women, and white men,
respectively.
| Discussion |
|---|
|
|
|---|
The prevalence of either clinical or subclinical vascular disease was
very high in older men and women, both black and white. Only 25% of
black women and 19% of black men had neither subclinical nor clinical
cardiovascular disease at age
65 years, compared with
32% of white women and 21% of white men. Black women had
significantly higher prevalence of clinical disease than white women.
The prevalence of subclinical disease increased with age in all four
race/sex groups. The distribution of the attributes of subclinical
disease is different for blacks and whites. Blacks had a greater
prevalence of common carotid artery wall thickness
80th percentile.
White men had a significantly higher prevalence of internal carotid
artery wall thickness
80th percentile than black men. Whites had a
much greater prevalence of carotid artery stenosis >25%
(Table 4
). Similar observations have been reported previously by the
CHS3 and the Atherosclerosis Risk
in Communities study.8
The absence of good genetic markers, ie, host susceptibility, detailed lifetime measures of risk factors, and other unmeasured risk factors, limits our interpretation of any differences in prevalence of components of subclinical disease (ie, ankle/brachial blood pressure, common and intimal carotid artery wall thickness) between blacks and whites.
Second, the risk factors for prevalent subclinical vascular disease and clinical disease among blacks were similar to those for whites. The interaction term of disease, sex, and race was significant only for systolic blood pressure. There was also a significant disease/race interaction for LDL-C levels, showing a stronger association for blacks, especially black women.
The lack of an association of history of hypertension with subclinical
disease among black women in multivariate
analysis is likely due to the very high prevalence of
hypertension, ie, 62% of those without subclinical disease versus 66%
with subclinical disease among black women. As noted in Table 5
, the
prevalence of hypertension was about 11/2 to 2 times as high for
black as for white women with no clinical or subclinical disease. As
the prevalence of any of these risk factors (eg, hypertension) begins
to approach 100% among participants without subclinical or clinical
disease, the likelihood of finding any significant associations across
prevalent disease categories becomes much smaller. For example, if all
black women were hypertensive, there clearly could be no way of
identifying any association of the risk factor (ie, hypertension) and
prevalent subclinical or clinical versus no disease in this study. The
prevalence of a history of diabetes was higher in blacks than whites
and in women than men for all prevalent subclinical or clinical
cardiovascular disease categories (see Table 5
),
consistent with the literature. The odds ratios for HDL-C,
white blood cell count, and family history of MI were similar for black
and white women.
The absence of significance for some of the variables in multiple logistic analysis for blacks compared with whites, in spite of similar point estimates, is due to much smaller sample sizes among blacks, especially black men. The significant variables in logistic regression are not necessarily the primary causal variables but provide a summary statistic of many interrelated variables in the causal pathway of atherosclerosis and clinical disease.
Third, the risk factor associations for older individuals for subclinical disease, especially systolic blood pressure, cigarette smoking, and measures of lipoproteins, were similar to risk factors for clinical cardiovascular disease among younger individuals.9 Diastolic blood pressure was lower for older individuals with clinical and subclinical disease.
The absence of a strong association of LDL-C and subclinical or
clinical cardiovascular disease among older
men10 11 12 could be related to selective survival
to older ages (eg, men with higher LDL-C cholesterol levels
have already died from cardiovascular disease),
possible decrease in LDL-C with increasing age,13
and the possibility of greater misclassification of subclinical and no
subclinical disease for older men compared with women because the
overall prevalence of atherosclerosis is higher in
older men than women. The lower prevalence of current cigarette smoking
among participants with clinical disease (Table 5
) may be due to (1)
changes in cigarette smoking after the onset of clinical disease, (2) a
higher mortality following the development of clinical disease among
cigarette smokers than noncigarette smokers, and (3) higher mortality
among smokers with subclinical disease.
BMI was not significantly associated with subclinical compared with no disease for black men and both black and white women, even before the inclusion of other cardiovascular risk factors in the multivariate analysis. The absence of an association of BMI with subclinical vascular disease among women was not primarily due to the confounding of the BMI with the other cardiovascular risk factors. Weight gain and obesity may be more important risk factors for cardiovascular disease among premenopausal and younger perimenopausal and postmenopausal women than among older women.14 15 16 17
BMI or waist measurements may be an inadequate measure of body fatness among older individuals.18 19 There is an increase in body fat percentage and a decrease in muscle and bone with increasing age, especially for women.20 21 The development of osteoporosis of the spine results in a decrease in the size of vertebral bodies and in compression fractures, with a concomitant loss of height, thereby modifying the estimated BMI (weight/[height]2 ).
Individual composites of subclinical disease are probably measures of systemic atherosclerotic disease. There are high correlations among the specific components, ie, ankle/brachial blood pressure and carotid artery wall thickness or stenosis, and each component has previously been shown to be a predictor of risk of clinical disease.22 23 24 25
There is not a perfect correlation of specific measures of atherosclerosis or subclinical disease at different anatomical sites. The measurement of subclinical disease at more than one anatomical site may provide a better distinction of subclinical from no subclinical disease than would measures limited to one anatomical site (ie, carotid or ankle/brachial blood pressure). It is important to recognize, however, that even this combination of measures of subclinical disease does not fully discriminate individuals with no disease from those with measures of subclinical atherosclerosis. There are errors associated with all of these measures. We did not have an independent noninvasive measure of the amount and characteristics of atherosclerosis in the coronary arteries.
We did not include echocardiographic measurements in this analysis. There is, however, a strong correlation in the CHS between electrocardiographic criteria for increased left ventricular mass and echocardiographic measurements.26 Both measures (ie, electrocardiographic and echocardiographic left ventricular mass) were related to similar risk factors, including prevalent clinical coronary artery disease, blood pressure levels, and obesity at baseline. Both electrocardiographic measures of ischemia and left ventricular hypertrophy and echocardiographic measures of left ventricular hypertrophy have been related to carotid artery disease.27 Left ventricular hypertrophy, based on both echocardiographic and electrocardiographic28 29 30 31 criteria, is much more prevalent in blacks than whites.
The relevance of this composite measure of subclinical disease for blacks compared with whites will ultimately depend on the ability of the index to predict clinical cardiovascular disease among blacks, as it has for whites.2 It is possible that the composite measure of subclinical disease will not have a similar relationship to either relative or attributable risk of cardiovascular disease for blacks compared with whites, because of differences in the components of subclinical disease, in which case, the individual measures of some clinical disease (ie, carotid artery disease, carotid stenosis, increased wall thickness in the common carotid artery, decreased ankle/brachial blood pressure) may be better measures for blacks than whites. Whether the composite index is a better predictor of clinical disease in terms of both relative and attributable risks compared with any of the specific components of subclinical disease (ie, carotid artery wall thickness, ankle/brachial blood pressure) or to traditional risk factors such as cholesterol and blood pressure levels32 will be determined.33
| Selected Abbreviations and Acronyms |
|---|
|
| Appendix 1 |
|---|
|
|
|---|
Forsyth County, NC; Bowman Gray School of Medicine, ECG Reading Center: Farida Rautaharju and Pentti Rautaharju.
Sacramento County, Calif; University of California, Davis: William Bommer, Charles Bernick, Andrew Duxbury, Mary Haan, Calvin Hirsch, Lawrence Laslett, Marshall Lee, John Robbins, and Richard White.
Washington County, Md; The Johns Hopkins University: M. Jan Busby-Whitehead, Joyce Chabot, George W. Comstock, Adrian Dobs, Linda P. Fried, Joel G. Hill, Steven J. Kittner, Shiriki Kumanyika, David Levine, Joao A. Lima, Neil R Powe, Thomas R Price, Jeff Williamson, Moyses Szklo, and Melvyn Tockman.
Washington County, Md; The Johns Hopkins University, MRI Reading Center: R Nick Bryan, Norman Beauchamp, Carolyn C. Meltzer, Naiyer Iman, Douglas Fellows, Melanie Hawkins, Patrice Holtz, Michael Kraut, Grace Lee, Larry Schertz, Cynthia Quinn, Earl P. Steinberg, Scott Wells, Linda Wilkins, and Nancy C. Yue.
Allegheny County, Pa; University of Pittsburgh: Diane G. Ives, Charles A. Jungreis, Laurie Knepper, Lewis H. Kuller, Elaine Meilahn, Peg Meyer, Roberta Moyer, Anne Newman, Richard Schulz, Vivienne E. Smith, and Sidney K Wolfson.
University of California, Irvine; Echocardiography Reading Center (baseline): Hoda Anton-Culver, Julius M. Gardin, Margaret Knoll, Tom Kurosaki, and Nathan Wong.
Georgetown Medical Center; Echocardiography Reading Center (follow-up): John Gottdiener, Eva Hausner, Stephen Kraus, Judy Gay, Sue Livengood, Mary Ann Yohe, and Retha Webb.
Geisinger Medical Center; Ultrasound Reading Center: Daniel H. O'Leary, Joseph F. Polak, and Laurie Funk.
University of Vermont; Central Blood Analysis Laboratory: Edwin Bovill, Elaine Cornell, Mary Cushman, and Russell P. Tracy.
University of Arizona, Tucson; Respiratory Sciences: Paul Enright.
University of Washington, Seattle; Coordinating Center: Alice Arnold, Annette L. Fitzpatrick, Bonnie K Lind, Richard A. Kronmal, Bruce M. Psaty, David S. Siscovick, Lynn Shemanski, Will Longstreth, Patricia W. Wahl, David Yanez, Paula Diehr, Maryann McBurnie, Chuck Spieker, Scott Emerson, Cathy Tangen, and Priscilla Velentgas.
NHLBI Project Office: Diane E. Bild, Robin Boineau, Teri A. Manolio, Peter J. Savage, and Patricia Smith.
| Acknowledgments |
|---|
Received July 8, 1997; accepted October 25, 1997.
| References |
|---|
|
|
|---|
2.
Kuller LH, Shemanski L, Psaty BM, Borhani NO, Gardin
J, Haan MN, O'Leary DH, Savage PJ, Tell GS, Tracy R. Subclinical
disease as an independent risk factor for
cardiovascular disease. Circulation. 1995;92:720726.
3. Manolio TA, Burke GL, Psaty BM, Newman AB, Haan M, Powe N, Tracy RP, O'Leary DH. Black-white differences in subclinical cardiovascular disease among older adults: the Cardiovascular Health Study. J Clin Epidemiol. 1995;48:11411152.[Medline] [Order article via Infotrieve]
4. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Tracy RP, Weiler PG, for the CHS Research Group. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263276.[Medline] [Order article via Infotrieve]
5. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358366.[Medline] [Order article via Infotrieve]
6.
Mittelmark MB, Psaty BM, Rautaharju PM, Fried LP,
Borhani NO, Tracy RP, Gardin JM, O'Leary DH. Prevalence of
cardiovascular diseases among older adults: the
Cardiovascular Health Study. Am J
Epidemiol. 1993;137:311317.
7.
Nieto FJ, Szklo M, Folsom AR, Rock R, Mercun M, for
the ARIC investigators. Leukocyte count correlates in middle-aged
adults: the Atherosclerosis Risk in Communities (ARIC)
Study. Am J Epidemiol. 1992;136:525537.
8.
Howard G, Sharrett AR, Heiss G, Evans GW, Chambless
LE, Riley WA, Burke GL, for the ARIC investigators. Carotid artery
intimal-medial thickness distribution in general populations as
evaluated by B-mode ultrasound. Stroke. 1993;24:12971304.
9.
Kannel WB, Wilson PWF. Risk factors that attenuate the
female coronary disease advantage. Arch Intern Med. 1995;155:5761.
10.
Ettinger WH, Wahl PW, Kuller LH, Bush TL, Tracy RP,
Manolio TA, Borhani NO, Wong ND, O'Leary DH, for the CHS Collaborative
Research Group. Lipoprotein lipids in older people: results from the
Cardiovascular Health Study. Circulation. 1992;86:858869.
11.
Weijenberg MP, Feskens EJM, Kromhout D. Total and high
density lipoprotein cholesterol as risk factors for
coronary heart disease in elderly men during 5 years of
follow-up: the Zutphen Elderly Study. Am J Epidemiol. 1996;143:151158.
12.
Iribarren C, Reed DM, Burchfield CM, Dwyer JH. Serum
total cholesterol and mortality: confounding factors and
risk modification in Japanese-American men. JAMA. 1995;273:19261982.
13. Newschaffer CJ, Bush TL, Hale WE. Aging and total cholesterol levels: cohort, period, and survivorship effects. Am J Epidemiol.. 1992;1:2334.
14.
Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter
DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality
among women. N Engl J Med. 1995;333:677685.
15. Stern M. Epidemiology of obesity and its link to heart disease. Metabolism. 1996;44:13.
16. Castelli WP, Wilson PWF, Levy D, Anderson K. Cardiovascular risk factors in the elderly. Am J Cardiol. 1989;63:12H19H.[Medline] [Order article via Infotrieve]
17. Tuomilehto J. Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on high blood pressure in the elderly. Am J Med. 1991;90:34S42S.[Medline] [Order article via Infotrieve]
18. Gallagher D, Visser M, Sepúlveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol.. 1996;1443:228239.
19.
Roubenoff R, Dallal GE, Wilson PWF. Predicting body
fatness: the body mass index vs estimation by bioelectric impedance.
Am J Public Health. 1995;85:726728.
20. Steiger P, Cummings SR, Black DM, Spencer NE, Genant HK. Age-related decrements in bone mineral density in women over 65. J Bone Miner Res. 1992;7:625632.[Medline] [Order article via Infotrieve]
21. Heitmann BL. The effects of gender and age on associations between blood lipid levels and obesity in Danish men and women aged 3565 years. J Clin Epidemiol. 1992;45:693702.[Medline] [Order article via Infotrieve]
22.
O'Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG,
Wolfson SK Jr, Bommer W, Price TR, Gardin JM, Savage PJ. Distribution
and correlates of sonographically detected carotid artery disease in
the Cardiovascular Health Study. Stroke. 1992;23:17521760.
23.
Crouse JR III, Craven TE, Hagaman AP, Bond MG.
Association of coronary disease with segment-specific
intimal-medial thickening of the extracranial carotid artery.
Circulation. 1995;92:11411147.
24. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA. 1993;27:487489.
25.
Sutton-Tyrrell K, Alcorn HG, Herzog H, Kelsey SF,
Kuller LH. Morbidity, mortality, and antihypertensive treatment effects
by extent of atherosclerosis in older adults with
isolated systolic hypertension. Stroke. 1995;26:13191324.
26.
Rautaharju PM, Manolio TA, Siscovick D, Zhou SH, Gardin
JM, Kronmal R, Furberg CD, Borhani NO, Newman A, for the
Cardiovascular Health Study Collaborative Research
Group. Utility of new electrocardiographic models for left
ventricular mass in older adults. Hypertension. 1996;28:815.
27.
Okin PM, Roman MJ, Devereux RB, Kligfield P.
Association of carotid atherosclerosis with
electrocardiographic myocardial ischemia and left
ventricular hypertrophy.
Hypertension. 1996;28:37.
28. Prineas RJ, Castle CH, Curb JD, Harris R, Lewin A, Stamler J. Hypertension detection and follow-up program: baseline electrocardiographic characteristics of the hypertensive participants. Hypertension. 1983;5:IV-160IV-189.
29. Rautaharju PM, LaCroiz AZ, Savage DD, Haynes SG, Madans JH, Wolf HK, Hadden W, Keller J, Cornoni-Huntley J. Electrocardiographic estimate of left ventricular mass versus radiographic cardiac size and the risk of cardiovascular disease mortality in the epidemiologic follow-up study of the First National Health and Nutrition Examination Survey. Am J Cardiol. 1988;62:5966.[Medline] [Order article via Infotrieve]
30.
Lee DK, Marantaz PR, Devereux RB, Kligfield P, Alderman
MH. Left ventricular hypertrophy in black and
white hypertensives: standard electrocardiographic criteria
overestimate racial differences in prevalence. JAMA. 1992;267:32943299.
31. Arnett DK, Strogatz DS, Ephross SA, Hames CG, Tyroler HA. Greater incidence of electrocardiographic left ventricular hypertrophy in black men than in white men in Evans County, Georgia. Ethn Dis. 1992;2:1017.[Medline] [Order article via Infotrieve]
32.
Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP,
Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J, for the
Systolic Hypertension in the Elderly Research Project:
coronary heart disease risk factors in men and women aged 60
years and older: findings from the Systolic Hypertension in the
Elderly Program. Circulation. 1996;94:2634.
33. Kannel W, D'Agostino R. The importance of cardiovascular risk factors in the elderly. Am J Geriatr Cardiol. 1995;4:10, 16, 1923.
This article has been cited by other articles:
![]() |
M. D. Walker, J. Fleischer, T. Rundek, D. J. McMahon, S. Homma, R. Sacco, and S. J. Silverberg Carotid Vascular Abnormalities in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3849 - 3856. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.C. Bennett, S. Silverman, P.S. Gill, and G.Y.H. Lip Ethnicity and peripheral artery disease QJM, January 1, 2009; 102(1): 3 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Rutger Persson, O. Ohlsson, T. Pettersson, and S. Renvert Chronic periodontitis, a significant relationship with acute myocardial infarction Eur. Heart J., December 1, 2003; 24(23): 2108 - 2115. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. J Kullo, K. R Bailey, S. L. Kardia, T. H Mosley Jr, E. Boerwinkle, and S. T Turner Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study Vascular Medicine, November 1, 2003; 8(4): 237 - 242. [Abstract] [PDF] |
||||
![]() |
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text] |
||||
![]() |
L. S. Kinsinger, R. Harris, S. H. Woolf, H. C. Sox, and K. N. Lohr Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 2, 2002; 137(1): 59 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Manolio and D. E. Bild Coronary Calcium, Race, and Genes Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 359 - 360. [Full Text] [PDF] |
||||
![]() |
A. B. Newman, B. L. Naydeck, J. Whittle, K. Sutton-Tyrrell, D. Edmundowicz, and L. H. Kuller Racial Differences in Coronary Artery Calcification in Older Adults Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 424 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Newman, B. L. Naydeck, K. Sutton-Tyrrell, A. Feldman, D. Edmundowicz, and L. H. Kuller Coronary Artery Calcification in Older Adults to Age 99: Prevalence and Risk Factors Circulation, November 27, 2001; 104(22): 2679 - 2684. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Geffken, M. Cushman, G. L. Burke, J. F. Polak, P. A. Sakkinen, and R. P. Tracy Association between Physical Activity and Markers of Inflammation in a Healthy Elderly Population Am. J. Epidemiol., February 1, 2001; 153(3): 242 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Kuller, P. Velentgas, J. Barzilay, N. J. Beauchamp, D. H. O’Leary, and P. J. Savage Diabetes Mellitus : Subclinical Cardiovascular Disease and Risk of Incident Cardiovascular Disease and All-Cause Mortality Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 823 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Taylor, L. L. Adams-Campbell, and J. T. Wright Jr. Risk/Benefit Assessment of Tamoxifen to Prevent Breast CancerStill a Work in Progress? J Natl Cancer Inst, November 3, 1999; 91(21): 1792 - 1793. [Full Text] [PDF] |
||||
![]() |
M. H. Gail, J. P. Costantino, J. Bryant, R. Croyle, L. Freedman, K. Helzlsouer, and V. Vogel Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1829 - 1846. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |